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Abstract Optical coherence tomography (OCT) is able to
identify thrombus. We detect the frequency of thrombus
inside the guiding catheter by OCT and its relationship with
clinical and procedural factors. We screened 77 patients who
underwent OCT pullbacks. Only patients with visible guid-
ing catheter were finally included (35) and divided into
thrombus (21) or no-thrombus group (14). Patients within
thrombus group were mostly males (100 vs. 71 %,
p = 0.05), with acute coronary syndrome (76 vs. 36 %,
p = 0.02) and received more frequently percutaneous cor-
onary intervention (86 vs. 43 %, p = 0.01) as compared to
other group. A second dose of heparin was more frequently
administered in thrombus than in other group (86 vs. 50 %,
p = 0.01). Time between first heparin administration and
OCT pullback (41[28–57] vs. 20 min [10–32], p = 0.001),
time elapsed from second heparin administration and OCT
pullback (29 [19–48] vs. 16 min [12–22], p = 0.002) and
total procedural time (47 [36–69] vs. 31 min [26–39],
p = 0.005) were longer in thrombus compared to other
group. At multivariate analysis, total procedural time and
time between first heparin administration and OCT pullback
were only predictors of intra-catheter thrombus (HR 0.6
[0.3–0.9], p = 0.03 and HR 1.9 [1.1–3.2], p = 0.02,
respectively). Thrombus inside guiding catheter may be a
frequent finding in long interventional procedure. Future
studies are warranted to determine its clinical impact.
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Introduction
Over last years, optical coherence tomography (OCT) has
contributed to clarify the pathophysiology of coronary
atherosclerosis [1–6]. Specifically, it is able to identify
plaque rupture, fibrous cap erosion and intracoronary
thrombus in patients with acute myocardial infarction, with
higher resolution as compared with other imaging tech-
niques [6–9]. In particular, OCT represents the gold stan-
dard for intra-coronary thrombus detection, which appears
as a mass attached to luminal surface or floating within the
lumen or as a mass protruding in-between or over stent
struts [4]. OCT is also capable to discriminate between 2
types of thrombus: red thrombus, characterized by high
light attenuation and white thrombus, homogeneous, with
low light attenuation [4].
Thrombus may be localized not only at intra-coronary
level but also in the guiding catheter. It may be caused by a
combination of the following: active and multiple instru-
mentation of the coronary artery during percutaneous cor-
onary intervention (PCI), insufficient flushing of the
guiding catheter; insufficient anticoagulation; instrumen-
tation of the coronary artery by manual thrombectomy
devices with fragmentation and loss of thrombus during
retrieval of the aspiration catheter [10]. However, inci-
dence and predictors of thrombus inside the guiding cath-
eter has not been systematically investigated.
In our study, we sought to define the frequency of
thrombus inside the guiding catheter by OCT and to
investigate its relationship with clinical and procedural
data.
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Methods
Study population
From September 2012 to September 2013, we screened all
consecutive patients who underwent OCT pullback in our
centre, selecting only those patients with visible guiding
catheter on OCT pullback. Study population was therefore
divided into two groups according to the presence of
thrombus inside the guiding catheter or not (thrombus
group and no thrombus group, respectively). Clinical and
procedural data, as well as in-hospital clinical adverse
events related to thrombus were recorded (acute myocar-
dial infarction, cardiac death and intra-stent thrombosis).
Procedural data
All patients were taking dual antiplatelet therapy with
aspirin and clopidogrel at least 24 h before the procedure.
According to the protocol of our Hospital, 5,000 IU of
unfractionated heparin were administered at the beginning
of coronary angiography and then, if PCI or OCT were
decided, a second dose of heparin was immediately
administered, according to patient’s weight, in order to
achieve the full dose of heparin (100 IU/kg). Instead, if
PCI or OCT were already planned before the coronary
angiography (e.g. OCT analysis of a stent previously
implanted, staged PCI, etc.) patients received a full amount
of heparin since the beginning of the interventional pro-
cedure. We did not perform activated coagulation time
(ACT) test. GPIIb/IIIa Inhibitors and bivalirudin were not
administered in any patient. Total procedural time was
measured from arterial puncture up to the removal of the
catheter from the coronary ostium. Thrombolysis in Myo-
cardial Infarction (TIMI) flow grade was also evaluated.
The following procedural data were collected:
1. the amount of the first dose of heparin;
2. the amount of the second dose of heparin;
3. the overall dose of heparin;
4. the time lag between the first and second heparin
administration (‘‘FH-SH time’’);
5. the time lag between the first heparin administration
and the OCT pullback (‘‘FH-OCT time’’);
6. the time lag between the second heparin administration
and the OCT pullback (‘‘SH-OCT time’’);
7. total procedural time.
The type of guiding catheter employed for each OCT
pullback was also reported.
All procedures performed in this study were in accor-
dance with the ethical standards of the institutional and/or
national research committee and with the 1964 Helsinki
declaration and its later amendments or comparable ethical
standards. An informed consent was obtained from all
patients.
Angiographic and OCT image acquisition and analysis
The OCT acquisition was performed using a commercially
available system for intra-coronary imaging (C7XR Fou-
rier-Domain System; LightLab Imaging, Westford Massa-
chusetts). Pullbacks were performed during continuous
injection of contrast medium (3 ml/s, Iodixanol 370,
Visipaque, GE Health Care, Cork, Ireland) through the
guide catheter with an injection pump. The automated
pullback rate was 20 mm/s and the frame rate was 100
frames. Intracoronary nitroglycerin bolus was always
administered before OCT pullback.
All angiographic and OCT images were analysed by two
independent observers blinded to clinical and procedural
data. In particular, OCT images were analysed using an
off-line review system (LightLab Imaging, Wesrford, MA,
USA). In OCT pullback, the length of the imaged guiding
catheter was measured and all frames with the guiding
catheter visible were analysed. The number of total frames
of guiding catheter and with visible thrombus were
recorded.
Thrombus, defined as a mass attached to luminal surface
or floating within the lumen [4] of the coronary or guiding
catheter (Fig. 1a–c) was measured in every frame and
reported as maximal, minimal and median thrombus area.
Thrombus volume and the distance of thrombus from the
ostium of guiding catheter were also reported. Finally,
thrombus images were also analysed on order to charac-
terize them as red, white or mixed thrombus [4].
Statistical analysis
Continuous variables are expressed as mean and standard
deviation (SD) or median and interquartile range (IQR), as
appropriate; categorical variables are reported as numbers
and percentages. Continuous variables were compared
between the two groups using independent t test or Mann–
Whitney U-test, as indicated, whereas proportions were
compared by Fisher’s exact. Linear regression model was
used to investigate the role of clinical and procedural
variables as predictors of thrombus inside the guiding
catheter.
In particular, univariate analysis was performed and
only variables retaining a statistical significant predictive
value (i.e. acute coronary syndrome, percutaneous coro-
nary intervention, number of patients who received a sec-
ond heparin administration, FH-OCT time, SH-OCT time,
total procedural time; two-tailed p value \0.05) were
included in a multivariable backward stepwise regression
analysis.
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The inter- and intra- observer agreement for OCT
measurement was quantified by the Cohen’s Kappa test for
concordance [11].
Data were analyzed using SPSS for Windows version
20.0 software (SPSS Inc. Chicago, USA).
Results
Population study
During the study period, 77 patients underwent OCT ana-
lysis (101 pullbacks overall) (Fig. 2). Forty patients (63
pullbacks) did not have the guiding catheter visible on
OCT pullback, whereas two patients (2 pullbacks) were
excluded due to artifacts on OCT pullback. Eventually, 35
patients (36 pullbacks) were included in this study. Out of
these, 21 patients (60 %) (22 pullbacks) had thrombus
inside guiding catheter (thrombus group) and the remaining
14 (40 %) (14 pullbacks) did not (no-thrombus group). Of
note, one patient of thrombus group received two OCT
pullbacks: at the end of the PCI for acute coronary syn-
drome (ACS), and at follow-up assessment 1 month later.
In both cases, OCT analysis showed thrombus inside the
guiding catheter.
Fig. 1 Thrombotic images by OCT into catheter guide. According
from the last consensus conference, thrombus was defined as a mass
attached to luminal surface or floating within the lumen of the
coronary or catheter guide (see blue arrows). The lengths of guiding
catheter are 10.2 mm (a), 13.2 mm (b) and 0.13.1 mm (c),
respectively
Fig. 2 Flow chart of the study. During the study period, 77 patients
underwent OCT pullbacks (101 pullbacks overall). Forty patients (63
pullbacks) did not show the guiding catheter, whereas two of them (2
pullbacks) were excluded for presence of image artifacts on OCT
pullback. Eventually, 35 patients (36 pullbacks) were enrolled in our
study. Out of these, 21 patients (60 %) (22 pullbacks) had thrombus
inside guiding catheter (thrombus group) and the remaining 14 (40 %)
(14 pullbacks) did not (no-thrombus group)
Table 1 Clinical characteristics of patients
Thrombus
group (21)
No thrombus
group (14)
p
Age, years (mean ± SD) 67.5 ± 10 61.7 ± 12 0.13
Gender, male, n (%) 21 (100) 10 (71) 0.05
Weight, kg, (range) 80 (75–95) 77 (69–83) 0.19
Hypertension, n (%) 14 (67) 11 (78) 0.23
Diabetes mellitus, n (%) 7 (33) 4 (28) 0.60
Dyslipidemia, n (%) 12 (57) 6 (43) 0.42
Smoking, n (%) 9 (43) 8 (57) 0.23
Acute coronary syndrome, n (%) 16 (76) 5 (36) 0.02
Chronic stable angina, n (%) 5 (24) 1 (7) 0.24
Silent ischemia, n (%) 0 (0) 1 (7) 0.38
Therapy
Aspirin, n (%) 21 (100) 14 (100) 1.0
Clopidogrel, n (%)* 21 (100) 14 (100) 1.0
Nitrates, n (%) 2 (9) 2 (14) 0.49
Beta blockers, n (%) 13 (62) 10 (71) 0.29
Calcium antagonist, n (%) 2 (0) 0 (0) 0.38
ACE-inhibitor, n (%) 19 (90) 11 (78) 0.54
Statins, n (%) 12 (57) 6 (43) 0.42
OCT optical coherence tomography, ACE-inhibitors angiotensin-
converting-enzyme inhibitor
* = at least 300 mg, after interventional procedure
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Clinical characteristics
Baseline features of patients are shown in Table 1.
There were no significant differences between groups in
term of age and cardiovascular risk factors (smoking,
hypertension, diabetes, dyslipidemia); however, patients
within thrombus group were preferentially males (100 vs.
71 %, p = 0.05) and admitted for ACS (76 vs. 36 %,
p = 0.02) as compared to no-thrombus group. Of note, in
both groups, ACS consisted only of no ST segment ele-
vation myocardial infarction (NSTEMI). No differences in
terms of medical therapy were reported between the two
groups. Fondaparinux was not administered in any patient.
No in- hospital clinical adverse events were observed.
Procedural characteristics and OCT analysis
Procedural data are reported in the Table 2, whereas the
data from OCT analysis are summarized by Table 3.
All the procedures were performed by radial approach
with 6 French guiding catheter. In the no-thrombus group,
OCT was performed more frequently for follow-up
assessment (50 %), compared to other group (p = 0.008).
Percutaneous coronary intervention was performed more
frequently in thrombus compared to no-thrombus group (86
vs. 43 %, p = 0.016). All patients presented TIMI 3 grade
flow before and after the procedure. No angiographic
images compatible with intra-coronary thrombus were
detected in any case. In particular, no intra-coronary
thrombus were detected in OCT pullbacks performed in
thrombus group. Accordingly, thrombus-aspiration was not
performed in any case.
Median length of imaged guiding catheter, analysed by
OCT, was 11.1 mm [8.07–17.55 mm]. The reproducibility
of thrombus detection inter and intra-observer variabilities
were 0.83 and 0.86 j, respectively. The overall number of
frames with thrombus was 58 (mean value 2.5 ± 1.5), thus
representing about the 4 % of the total guiding catheter
frames (1,463). The mean overall thrombus area was
20 lm2 [10–40 lm2], whereas thrombus median volume
was 0.17 lm3 [0.1–4.3 lm3].
The mean distance of the clots from the ostium of the
guiding catheters was 7.25 ± 5.6 mm.
Moreover, within the thrombus group, 91 % of throm-
bus were defined as white, while the remaining as red
(Table 3). There are no differences in frequency of
thrombus detected in the right compared to left catheters
(p = 0.59) and among the various guiding catheters used
(p = 0.97).
Total procedural time was longer in thrombus group
compared to the other group (p = 0.005, Fig. 3a). There
were no differences between groups in the amount of first,
second and overall dose of heparin. However, thrombus
group patients received more often a second dose of hep-
arin compared to the other group (86 vs. 50 %, p = 0.042).
‘‘FH-OCT time’’ (p = 0.001, Fig. 3b) and ‘‘SH-OCT
time’’ (p = 0.026, Fig. 3c) were longer in the thrombus
compared to no-thrombus group. Conversely, the ‘‘FH-SH
time’’ was the same between groups (Fig. 3d).
At multivariate analysis, total procedural time and the
‘‘FH-OCT time’’ were the only predictors of thrombus
inside the guiding catheter (HR 0.6 [0.37–0.96], p = 0.03
and HR 1.9 [1.1–3.2], p = 0.02, respectively).
Discussion
In our study we demonstrated that (1) thrombotic images
are detected by OCT in more than half of guiding catheters,
Table 2 Procedural characteristics
Thrombus group
(n 21)
(pullbacks 22)
No thrombus
group (n 14)
(pullbacks 14)
p
PCI, n (%) 19 (86) 6 (43) 0.01
Guiding catheter type 0.97
EBU 3.5, n (%) 6 (27) 3 (21)
JL 3.5, n (%) 8 (36) 6 (42)
JR 4, n (%) 1 (4) 0 (0)
AL 1, n (%) 7 (32) 5 (35)
OCT performed for
follow-up
assessment, n (%)
2 (9) 7 (50) 0.008
First dose of heparin
amount, IU
(mean ± SD)
5,700 (±1,572) 6,107 (±1,903) 0.17
Second dose of
heparin amount, IU,
(mean ± SD)
3,300 (±1,917) 2,800 (±636) 0.81
Total heparin
amount, IU,
(mean ± SD)
8,156 (±1,670) 7,500 (±1,270) 0.63
Patients receiving a
second dose of
heparin, n (%)
19 (86) 7 (50) 0.01
Total procedural
time, min [IQR]
47 [36–69] 31 [26–39] 0.005
FH-SH time, min
[IQT]
14 [12–16] 13 [12–16] 0.80
FH-OCT time, min,
[IQR]
41 [28–57] 20 [10–32] 0.001
SH-OCT time, min,
[IQR]
29 [19–48] 16 [12–22] 0.02
Guide catheter
length, mm, [IQR]
11.1 [7.7–13.2] 11.0 [8.0–12.0] 0.27
PCI percutaneous coronary intervention, IQR inter-quartile range, SD
standard deviation, OCT optical coherence tomography
242 Int J Cardiovasc Imaging (2015) 31:239–246
123
preferentially in ACS patients submitted to PCI; (2)
patients included in thrombus group received more fre-
quently a second dose of heparin compared to those in no-
thrombus group, although no difference in overall dose of
heparin was detected; (3) total procedural time, as well as
the time lag between the administration of each dose of
heparin and OCT pullback, were longer in thrombus than
no-thrombus group.
Over the last years, previous reports have been mostly
focused on thrombotic images localized at intra-coronary
levels [12–15], emphasizing its remarkable etiologic role in
ACS with elevated thrombotic burden and pro thrombotic
milieu [16, 17].
On the other hand, several studies have been focused on
thrombotic images localized at intra-stent level, mostly by
using imaging technique as OCT and Intravascular Ultra-
sound study [18–21].
Afterward, Yusuf et al. [22] reported that thrombus
images might be detected also inside the guiding catheter.
In particular they showed that, in a subgroup of ACS
patients treated with fondaparinux who underwent PCI,
there was an increased incidence of catheter thrombosis-
related events compared to those who received enoxaparin
(0.9 vs. 0.4 %, p \ 0.001). These findings suggest that,
although fondaparinux is beneficial for the overall ACS
patient population, there is a need for additional antico-
agulation treatment during PCI. Accordingly, in the Switch
III trial [23], an open-label prospective, randomized, mul-
ticenter pilot study aiming at comparing treatment with
unfractionated heparin versus bivalirudin in NSTEMI
patients initially treated with fondaparinux and undergoing
PCI, no catheter thrombosis-related events were detected in
both two arms.
Table 3 Data from OCT analysis
OCT parameters
Total guiding catheter frames, n 1,463
Frames with thrombus, n 58
Frames with thrombus, n (mean ± SD) 2.5 ± 1.5
Thrombus characterization
Red thrombus, n (%) 2 (9 %)
White thrombus, n (%) 20 (91 %)
Thrombus area values
Median volume, lm3 [range] 0.17 [0.1–4.3]
Maximal area value, lm2, [range] 40 [20–60]
Minimal area value, lm2, [range] 20 [10–20]
Median area value, lm2, [range] 20 [10–40]
OCT optical coherence tomography
Fig. 3 a. Box plot showing the differences for the total procedural
time, between the two groups, thrombotic group and no thrombotic
group. Data are expressed as median [interquartile range]. b. Box plot
showing the differences for the lag time between the first heparin
administration and the OCT pullback (‘‘FH-OCT time’’) in the two
groups (thrombus group and no thrombus group). Data are expressed
as median [interquartile range]. c. Box plot showing the differences
for the lag time between the second heparin administration and the
OCT pullback (‘‘SH-OCT time’’) in the two groups (thrombus group
and no thrombus group). Data are expressed as median [interquartile
range]. d. Box plot showing the differences for the lag time between
the first heparin and the second heparin administration (‘‘FH-SH
time’’) in the two groups (thrombus group and no thrombus group).
Data are expressed as median [interquartile range]
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In our series, where heparin was the only anticoagulant
used during coronary angiography, we identified thrombus
images in 60 % of patients with unintentional guiding
catheter image acquisition by OCT.
The higher rate of catheter thrombosis in comparison
with Yusuf’ data (60 vs. 0.6 %) might be explained by the
use, in our study, of the most sensitive imaging technique
for thrombus detection.
Of note, we should also speculate that, just before OCT
analysis, the interventional manouvers and also the inten-
sity of flushing might have impact on these tiny thrombus
formations inside the guiding catheter.
In detail, we showed that patients with thrombus image
inside the guiding catheter performed OCT more fre-
quently at the end of PCI, requiring two doses of heparin
for the achievement of full amount. On the contrary,
patients without thrombus inside guiding catheter, per-
formed OCT more preferentially for follow-up assessment,
thus receiving a full amount of heparin since the beginning
of the interventional procedure. Of note, the same total
amount of heparin was detected in both study groups.
Moreover, a longer total procedural time, as well as the
longer time between the administration of each dose of
heparin and OCT pullback, were detected in patients with
compared to those without intra-catheter thrombus image.
Finally, the multivariate analysis showed that total proce-
dural time and time between the administration of first dose
of heparin and OCT pullback were independent predictors
of intra-catheter thrombus. Taken together, our data high-
light the crucial role of a long-lasting interventional pro-
cedure in intra-catheter thrombus formation.
Anticoagulant therapy is necessary in trans radial
approach, to reduce the risks of radial artery occlusion
after trans-radial catheterisation. In this context, Spaulding
et al. showed that 5,000 IU of heparin are able to reduce
the incidence of radial artery occlusion [24, 25]. According
to these results, in the routine clinical practice of our
Hospital, 5,000 IU of heparin are currently administered
immediately after radial sheath introduction, at the begin-
ning of the coronary angiography. Optimal anticoagulation
is paramount during interventional procedures and ACT
monitoring during long-lasting procedures is endorsed
from the guidelines [26]. For PCI, the recommended target
ACT is 250–300 s; unless abciximab is used, when a lower
target ACT value (about 200 s) is recommended [26]. ACT
could play therefore a remarkable role both for the timing
of administration and the choice of the proper dose of
heparin.
In our study, thrombus formation could probably be
associated with an insufficient anticoagulation. A possible
explication of this phenomenon might be found in the
considerable individual variability of heparin clearance
from the bloodstream [27].
In particular, after parenteral injection, heparin is
removed from the blood via two mechanisms, saturable and
non-saturable. At dose of 5,000 IU, unfractionated heparin
is removed mainly via the saturable mechanism. In our
context, only after a complete saturation of its degradation
systems, the increase of heparin concentration becomes
linear [27]. The saturable clearance of this drug, accounts
for the dose-dependent half-life of the heparin. For this
reason, it is reasonable to choose a starting weight or body
surface area based dose.
These data might explain the more frequent incidence of
intra-catheter thrombus in patients receiving two fractioned
sub-optimal doses of heparin compared to cases treated
with a single weight based dose, administered from the
beginning.
In this context, our data seem to suggest that, especially
when a long-lasting interventional procedure is expected, it
is reasonable to choose directly a starting weight based
heparin dose in order to avoid an insufficient anticoagulation.
However, future larger dose-ranging studies, providing a
systematical ACT monitoring during PCI, are required to
clarify this point.
Study limitations
Our study presents several limitations: (1) although it
represents the first contribution to detect the incidence of
thrombus inside the guiding catheter by OCT, the small
simple size requires to be expanded in future larger studies;
(2) we did not provide a systematical evaluation of the
heparin effect by ACT during the procedure; (3) new
anticoagulants, as bivalirudin, were not used; (4) the small
sample size does not allow to properly evaluate clinical
events related to thrombus; (5) considering the retrospec-
tive nature of the study, we were not able to perform the
histological analysis of the guiding catheter.
Conclusion
Thrombus inside guiding catheter represents a frequent
finding in unintentional OCT image acquisition, especially
in long-lasting interventional procedure. Future studies are
warranted to determine its clinical impact.
Conflict of interest The authors declare that they have no conflict
of interest.
Ethical standards The authors state that this study have been
approved by the appropriate ethics committee and have therefore been
performed in accordance with the ethical standards laid down in the
1964 Declaration of Helsinki and its later amendments.
Informed consent Informed consent was obtained from all indi-
vidual participants included in the study
244 Int J Cardiovasc Imaging (2015) 31:239–246
123
References
1. Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG,
Chang W, Hee MR, Flotte T, Gregory K, Puliafito CA (1991)
Optical coherence tomography. Science 254:1178–1181
2. Bezerra HG, Costa MA, Guagliumi G, Rollins AM, Simon DI
(2009) Intracoronary optical coherence tomography: a compre-
hensive review clinical and research applications. JACC Car-
diovasc Interv 2:1035–1046
3. Kubo T, Akasaka T (2010) Optical coherence tomography
imaging: current status and future perspectives : current and
future developments in OCT. Cardiovasc Interv Ther 25:2–10
4. Tearney GJ, Regar E, Akasaka T, Adriaenssens T, Barlis P,
Bezerra HG, Bouma B, Bruining N, Cho JM, Chowdhary S,
Costa MA, de Silva R, Dijkstra J, Di Mario C, Dudek D, Falk E,
Feldman MD, Fitzgerald P, Garcia-Garcia HM, Gonzalo N,
Granada JF, Guagliumi G, Holm NR, Honda Y, Ikeno F, Ka-
wasaki M, Kochman J, Koltowski L, Kubo T, Kume T, Kyono H,
Lam CC, Lamouche G, Lee DP, Leon MB, Maehara A, Manfrini
O, Mintz GS, Mizuno K, Morel MA, Nadkarni S, Okura H, Otake
H, Pietrasik A, Prati F, Ra¨ber L, Radu MD, Rieber J, Riga M,
Rollins A, Rosenberg M, Sirbu V, Serruys PW, Shimada K,
Shinke T, Shite J, Siegel E, Sonoda S, Suter M, Takarada S,
Tanaka A, Terashima M, Thim T, Uemura S, Ughi GJ, van
Beusekom HM, van der Steen AF, van Es GA, van Soest G,
Virmani R, Waxman S, Weissman NJ, Weisz G, International
Working Group for Intravascular Optical Coherence Tomography
(IWG-IVOCT) (2012) Consensus standards for acquisition,
measurement, and reporting of intravascular optical coherence
tomography studies. J Am Coll Cardiol 59:1058–1072
5. Jang IK, Tearney GJ, MacNeill B, Takano M, Moselewski F,
Iftima N, Shishkov M, Houser S, Aretz HT, Halpern EF, Bouma
BE (2005) In vivo characterization of coronary atherosclerotic
plaque by use of optical coherence tomography. Circulation
111:1551–1555
6. Gonzalo N, Serruys PW, Barlis P, Ligthart J, Garcia-Garcia HM,
Regar E (2010) Multi-modality intra-coronary plaque character-
ization: a pilot study. Int J Cardiol 138:32–39
7. Motoyama S, Sarai M, Harigaya H, Anno H, Inoue K, Hara T,
Naruse H, Ishii J, Hishida H, Wong ND, Virmani R, Kondo T,
Ozaki Y, Narula J (2009) Computed tomographic angiography
characteristics of atherosclerotic plaques subsequently resulting
in acute coronary syndrome. J Am Coll Cardiol 54:49–57
8. Kubo T, Imanishi T, Takarada S, Kuroi A, Ueno S, Yamano T,
Tanimoto T, Matsuo Y, Masho T, Kitabata H, Tsuda K, Tomo-
buchi Y, Akasaka T (2007) Assessment of culprit lesion mor-
phology in acute myocardial infarction: ability of optical
coherence tomography compared with intravascular ultrasound
and coronary angioscopy. J Am Coll Cardiol 50:933–939
9. Ozaki Y, Okumura M, Ismail TF, Motoyama S, Naruse H, Hattori
K, Kawai H, Sarai M, Takagi Y, Ishii J, Anno H, Virmani R,
Serruys PW, Narula J (2011) Coronary CT angiographic char-
acteristics of culprit lesions in acute coronary syndromes not
related to plaque rupture as defined by optical coherence
tomography and angioscopy. Eur Heart J 32:2814–2823
10. Eeckhout E, Serruys PW, Wijns W, Vahanian A, van Sambeek
M, De Palma R (eds) (2012) PCR–EAPCI textbook of percuta-
neous interventional cardiovascular medicine. Europa Publica-
tions, London
11. Cohen J (1960) A coefficient of agreement for nominal scales.
Educ Psychol Meas 20:37–46
12. Vetrovec GW, Cowley MJ, Overton H, Richardson DW (1981)
Intracoronary thrombus in syndromes of unstable myocardial
ischemia. Am Heart J 102:1202–1208
13. Holmes DR Jr, Hartzler GO, Smith HC, Fuster V (1981) Coro-
nary artery thrombosis in patients with unstable angina. Br Heart
J 45:411–416
14. Ellis SG, Roubin GS, King SB, Douglas JS Jr, Weintraub WS,
Thomas RG, Cox WR (1988) Angiographic and clinical predic-
tors of acute closure after native vessel coronary angioplasty.
Circulation 77:372–379
15. Singh M, Reeder GS, Ohman EM, Mathew V, Hillegass WB,
Anderson RD, Gallup DS, Garratt KN, Holmes DR Jr (2001)
Does the presence of thrombus seen on a coronary angiogram
affect the outcome after percutaneous coronary angioplasty? An
Angiographic Trials Pool data experience. J Am Coll Cardiol
38:624–630
16. Kirtane AJ, Sandhu P, Mehran R, McEntegart M, Cristea E,
Brener SJ, Xu K, Fahy M, Ge´ne´reux P, Wessler JD, Stone GW
(2014) Association between intraprocedural thrombotic events
and adverse outcomes after primary percutaneous coronary
intervention for st-segment elevation myocardial infarction (a
harmonizing outcomes with revascularization and stents in acute
myocardial infarction [HORIZONS-AMI] substudy). Am J Car-
diol 113:36–43
17. McEntegart MB, Kirtane AJ, Cristea E, Brener S, Mehran R,
Fahy M, Moses JW, Stone GW (2012) Intraprocedural throm-
botic events during percutaneous coronary intervention in
patients with non-ST-segment elevation acute coronary syn-
dromes are associated with adverse outcomes: analysis from the
ACUITY (Acute Catheterization and Urgent Intervention Triage
Strategy) trial. J Am Coll Cardiol 59:1745–1751
18. Otake H, Shite J, Ako J, Hinke T, Tanino Y, Ogasawara D,
Sawada T, Miyoshi N, Kato H, Koo BK, Honda Y, Fitzgerald PJ,
Hirata K (2012) Local determinants of thrombus formation fol-
lowing sirolimus-eluting stent implantation assessed by optical
coherence tomography. JACC Cardiovasc Interv 2:459–466
19. Awata M, Kotani J, Uematsu M, Morozumi T, Watanabe T,
Onishi T, Iida O, Sera F, Nanto S, Hori M, Nagata S (2007) Serial
angioscopic evidence of incomplete neointimal coverage after
sirolimus-eluting stent implantation: comparison with bare-metal
stents. Circulation 116:910–916
20. Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamig-
uchi H, Mintz GS, Nagata S (2006) Incomplete neointimal cov-
erage of sirolimus-eluting stents: angioscopic findings. J Am Coll
Cardiol 47:2108–2111
21. Takano M, Ohba T, Inami S, Seimiya K, Sakai S, Mizuno K (2006)
Angioscopic differences in neointimal coverage and in persistence
of thrombus between sirolimus-eluting stents and bare metal stents
after a 6-month implantation. Eur Heart J 27:2189–2195
22. Howe Fifth Organization to Assess Strategies in Acute Ischemic
Syndromes Investigators, Yusuf S, Mehta SR, Chrolavicius S,
Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP,
Wallentin L, Joyner C, Fox KA (2006) Comparison of fonda-
parinux and enoxaparin in acute coronary syndromes. N Engl J
Med 354:1464–1476
23. Waksman R, Bertrand O, Driesman M, Gruberg L, Rossi J, Mehta
S, Swymelar S, Dvir D, Xue Z, Torguson R (2013) Bivalirudin
versus unfractionated heparin during percutaneous coronary
intervention in patients with non-ST-segment elevation acute
coronary syndrome initially treated with fondaparinux: results
from an international, multicenter, randomized pilot study
(SWITCH III). J Interv Cardiol 26:107–113
24. Spaulding C, Lefevre T, Funck F, The´bault B, Chauveau M, Ben
Hamda K, Chalet Y, Monse´gu H, Tsocanakis O, Py A, Guillard
N, Weber S (1996) Left radial approach for coronary angiogra-
phy: results of a prospective study. Cathet Cardiovasc Diagn
39:365–370
Int J Cardiovasc Imaging (2015) 31:239–246 245
123
25. Bernat I, Bertrand OF, Rokyta R, Kacer M, Pesek J, Koza J, Smid
M, Bruhova H, Sterbakova G, Stepankova L, Costerousse O
(2011) Efficacy and safety of transient ulnar artery compression
to recanalize acute radial artery occlusion after transradial cath-
eterization. Am J Cardiol 107:1698–1701
26. Cavusoglu E, Lakhani M, Marmur JD (2005) The activated
clotting time (ACT) can be used to monitor enoxaparin and
dalteparin after intravenous administration. J Invasive Cardiol
17:416–421
27. De Swart CA, Nijmeyer B, Roelofs JM, Sixma JJ (1982) Kinetics
of intravenously administered heparin in normal humans. Blood
60:1251–1258
246 Int J Cardiovasc Imaging (2015) 31:239–246
123
